Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial
Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial. // Digestive and Liver Disease. – URL: https://www.sciencedirect.com/science/article/pii/S1590865826009862?dgcid=rss_sd_all
Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial. Digestive and Liver Disease. https://www.sciencedirect.com/science/article/pii/S1590865826009862?dgcid=rss_sd_all
“Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial.” Digestive and Liver Disease.
@article{article89073,
title = {Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial},
journal = {Digestive and Liver Disease},
url = {https://www.sciencedirect.com/science/article/pii/S1590865826009862?dgcid=rss_sd_all}
}